The Hook
Take a supplement for six weeks and your muscle cells' energy machinery looks measurably tighter. Then you climb on a bike, ride hard until you can't continue, and nothing changes.
That is the result of a new randomized trial of ubiquinol, the "active" form of coenzyme Q10. It is a good reminder that a better lab readout is not the same as a better performance outcome.
The Study at a Glance
A team led by researchers at Loughborough University, with Stephen Bailey as corresponding author, published the trial in the European Journal of Applied Physiology (2026; 126(9):4763-4778). They randomized 54 healthy, recreationally active males to either 300 mg per day of ubiquinol or a placebo for six weeks. The design was double-blind with independent groups.
Before and after supplementation, the researchers measured:
- Skeletal muscle mitochondrial respiration
- Muscle protein content of two "leak" proteins, ANT1+2 and UCP-3
- Performance on a severe-intensity cycling test to exhaustion, including time to the limit of tolerance (TLim) and oxygen uptake (V̇O2) kinetics
Ubiquinol vs. Ubiquinone: What's the Difference?
Coenzyme Q10 is part of the mitochondrial electron transfer system, the chain of reactions that helps your cells turn fuel and oxygen into usable energy. It comes in two forms:
- Ubiquinone is the oxidized form, and it is the one most supplement research has used.
- Ubiquinol is the reduced form. According to the authors, it has greater bioavailability than ubiquinone.
The authors note that most earlier studies gave ubiquinone and saw no effect on mitochondrial respiratory function or endurance performance. Ubiquinol's better absorption raised an obvious question: would the reduced form do what the oxidized form didn't? This trial tested that.
The Striking Finding: Tighter Mitochondrial Coupling
The ubiquinol group's plasma CoQ10 rose compared with both their own baseline and the placebo group, so the supplement was absorbed and raised blood levels.
The headline result was in muscle. Ubiquinol lowered the inverse respiratory control ratio, a measure of how tightly mitochondrial respiration is coupled to ATP production. Lower values suggest better oxidative phosphorylation coupling efficiency.
The reported values:
| Group | Before | After |
|---|---|---|
| Placebo | 0.064 ± 0.034 | 0.072 ± 0.026 |
| Ubiquinol | 0.073 ± 0.039 | 0.044 ± 0.019 |
The difference was statistically significant (P < 0.05). In plain terms, the muscle mitochondria of the ubiquinol group looked more efficiently coupled after six weeks. The authors describe this as "suggestive of" improved efficiency, which is more cautious than proof of better function.
Two caveats are worth noting. The ubiquinol group started slightly higher than the placebo group, and the standard deviations are large relative to the averages. The authors made the comparison against both baseline and placebo, as reported, but the numbers show considerable person-to-person variability.
The Plot Twist: No Performance Gain
Better coupling did not translate into better exercise results:
- Time to exhaustion (TLim) in the severe-intensity cycle test did not differ between groups.
- End-exercise V̇O2 and the change in V̇O2 between 2 minutes and end-exercise did not differ either.
- ANT1+2 and UCP-3 protein content did not change between groups. The researchers had examined these leak proteins as a possible explanation for the coupling shift, and the data didn't support it.
So the mechanism behind the improved coupling remains unexplained by this study. The paper doesn't say why the coupling result didn't show up in performance. Possible reasons include a modest effect size, a test that isn't sensitive to this change, or a population already at healthy baseline function. Those are possibilities, not findings.
Who Funded It?
The study was part of the first author's doctoral research, which was match-funded by Kaneka Pharma Europe and Loughborough University. Kaneka is a ubiquinol manufacturer. According to the paper's declaration, Kaneka had no role in interpreting the findings or preparing the manuscript. The company analyzed plasma samples for CoQ10 concentrations but was blinded throughout. The funding source doesn't invalidate the results, and notably the headline performance outcome was null, but readers should know about it.
Practical Takeaways
What the trial used: 300 mg of ubiquinol daily for six weeks. That is the only dose tested, so it's the only one this paper can speak to.
Timing and food: The abstract doesn't specify when participants took it. As general background, not a finding from this paper, CoQ10 is fat-soluble and is commonly taken with a meal containing some fat.
- People interested in mitochondrial health generally. The coupling result is a biomarker-level signal, not a proven health benefit.
- Older adults and people taking statins are often discussed in CoQ10 conversations. Those groups were not studied here, so this paper makes no claims about them. The participants were healthy, recreationally active males.
Who should probably skip it, or at least temper expectations:
- Anyone buying it to improve endurance. In this trial, six weeks of ubiquinol did not improve time to exhaustion or V̇O2 kinetics.
- Anyone expecting results from this study to apply to women, older adults, or people with medical conditions. Those groups weren't tested.
- Anyone on prescription medication or with a health condition should check with a clinician before starting any supplement.
Bottom Line
Ubiquinol did something measurable inside muscle cells. It raised plasma CoQ10 and appeared to improve mitochondrial coupling efficiency. But in healthy, active men, that didn't show up as a longer ride to exhaustion. For now it is a mechanistic curiosity rather than a performance tool, and the question of who might actually benefit remains open.
Citation: Acton JP, Alsharif NS, Bond JW, et al. Effect of six weeks ubiquinol supplementation on mitochondrial respiratory function and exercise capacity in healthy males. Eur J Appl Physiol. 2026;126(9):4763-4778. DOI: 10.1007/s00421-026-06275-w. PubMed: 42249931.